Systemic and mucosal immune responses to sublingual or intramuscular human papilloma virus antigens in healthy female volunteers

PLoS One. 2012;7(3):e33736. doi: 10.1371/journal.pone.0033736. Epub 2012 Mar 16.

Abstract

The sublingual route has been proposed as a needle-free option to induce systemic and mucosal immune protection against viral infections. In a translational study of systemic and mucosal humoral immune responses to sublingual or systemically administered viral antigens, eighteen healthy female volunteers aged 19-31 years received three immunizations with a quadravalent Human Papilloma Virus vaccine at 0, 4 and 16 weeks as sublingual drops (SL, n = 12) or intramuscular injection (IM, n = 6). IM antigen delivery induced or boosted HPV-specific serum IgG and pseudovirus-neutralizing antibodies, HPV-specific cervical and vaginal IgG, and elicited circulating IgG and IgA antibody secreting cells. SL antigens induced ~38-fold lower serum and ~2-fold lower cervical/vaginal IgG than IM delivery, and induced or boosted serum virus neutralizing antibody in only 3/12 subjects. Neither route reproducibly induced HPV-specific mucosal IgA. Alternative delivery systems and adjuvants will be required to enhance and evaluate immune responses following sublingual immunization in humans.

Trial registration: ClinicalTrials.govNCT00949572.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Sublingual
  • Adult
  • Alphapapillomavirus / immunology*
  • Antibodies, Neutralizing / biosynthesis
  • Antibodies, Neutralizing / blood
  • Antibodies, Viral / biosynthesis
  • Antibodies, Viral / blood
  • Antigens, Viral / administration & dosage*
  • Capsid Proteins / immunology
  • Cervix Uteri / immunology
  • Female
  • Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
  • Human papillomavirus 11 / immunology
  • Human papillomavirus 16 / immunology
  • Human papillomavirus 18 / immunology
  • Human papillomavirus 6 / immunology
  • Humans
  • Immunity, Mucosal
  • Immunoglobulin A, Secretory / biosynthesis
  • Immunoglobulin G / biosynthesis
  • Immunoglobulin G / blood
  • Injections, Intramuscular
  • Oncogene Proteins, Viral / immunology
  • Papillomavirus Vaccines / administration & dosage*
  • Vagina / immunology
  • Young Adult

Substances

  • Antibodies, Neutralizing
  • Antibodies, Viral
  • Antigens, Viral
  • Capsid Proteins
  • Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
  • Immunoglobulin A, Secretory
  • Immunoglobulin G
  • L1 protein, Human papillomavirus type 11
  • Oncogene Proteins, Viral
  • Papillomavirus Vaccines
  • L1 protein, Human papillomavirus type 6
  • L1 protein, Human papillomavirus type 16
  • L1 protein, Human papillomavirus type 18

Associated data

  • ClinicalTrials.gov/NCT00949572